Navigation Links
Zix Corporation Reports Another Record-High Revenue Quarter as Company Announces Second Quarter 2009 Financial Results
Date:7/28/2009

,000 hospitals. ZixCorp's PocketScript(R) e-prescribing service saves lives and saves money by automating the prescription process between payors, doctors and pharmacies. For more information, visit http://www.zixcorp.com/.

Safe Harbor Statement for ZixCorp

The following is a "Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995. Many of the foregoing statements by Mr. Spurr are forward-looking statements, not a guarantee of future performance, and involve substantial risks and uncertainties. Actual results may differ materially from those projected in these forward-looking statements. These risks and uncertainties include, but are not limited to, the following: the fact that the preliminary financial results included in this press release could be subject to change based on adjustments that are deemed appropriate by the Company during the process of finalizing its quarterly financial statements; the Company's continued operating losses and its PocketScript e-Prescribing service's use of cash resources; the Company's ability to achieve broad market acceptance for the Company's products and services, including the Company's ability to enter into new or expand existing sponsorship agreements for its PocketScript e-Prescribing business and the Company's ability to continue realizing acceptance of its Email Encryption business in its core markets of healthcare and financial and to achieve market acceptance of its Email Encryption business in other markets; the Company's ability to maintain existing and generate other revenue opportunities, including fees for scripts written or value added services for its payor customers from its PocketScript e-Prescribing business; the Company's ability to establish an
'/>"/>

SOURCE Zix Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related medicine news :

1. DURECT Corporation Invites You to Join Its Second Quarter 2009 Earnings Conference Call
2. Danaher Corporation Announces Retirement of Executive Vice President Philip W. Knisely
3. Dialysis Corporation of America Announces Second Quarter 2009 Earnings Release Date
4. Providence Service Corporation to Report Second Quarter 2009 Results on Monday, August 10th After the Market Closes
5. MedCath Corporation to Hold Conference Call on Third Quarter Results
6. Digirad Corporation Reports Second Quarter 2009 Financial Results
7. Service Corporation International Announces Schedule For Its Second Quarter 2009 Earnings Release and Conference Call
8. Quigley Corporation Announces Final Results of Quigley Pharmas Phase IIb Study
9. Align Technology Provides Update on Patent Litigation with Ormco Corporation
10. PTS, Inc. Subsidiary Disability Access Corporation Announces $535,000 in New Contracts and Inspection Orders for July 2009
11. PTS, Inc. Subsidiary Disability Access Corporation Announces $535,000 in New Contracts and Inspection Orders for July 2009

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2009)...ers from the North Pole, Textsanta.net lets parent...a , North Pole, AK (PRWEB...cies at the North Pole Santa Claus has added SMS t...lobe informed of his Christmas progress at the Nor...tment have identified a large and growing percenta...
(Date:11/26/2009)...Ennis, P.A. is offering free nationwide confidenti... control pills who have suffered a Deep Vein Throm...ack or other related cardiac issues or had their G...800-856-6405 or go to the firm’s website at ...ase evaluation form. , (P...
(Date:11/25/2009)...swire/-SentinelleMedicalInc.,aleadingmanufacturero...algaryScientificInc.,aleadingproviderofsoftwareena...(TM)Breast4DAdvancedVisualizationsoftware. ,, T...tWebclientbasedmedicalimagingofferinginthemarket.C...-footprintaccess-requiringnosoftwaredownload,andru...
(Date:11/25/2009)...SNewswire/--TheBlackAIDSInstituterecentlyheldBoard...or2010. ,, ThenewBoardMembersareahighlydiverseg...ance,governmenthealthprograms,editorial,andbusines...fpersonalbackgroundsincludingbothheterosexualandga...epresentingmultipleagegroups. ,, (Photo: http:/...
(Date:11/25/2009)... statistically significant survival benefit from a...ceptor (ER)-positive tumors had high levels of pho...S118-P), according to a brief communication publis...onal Cancer Institute . , Approximately 50% of b...inical studies have shown that ER-alpha S118-P is ...
Breaking Medicine News(10 mins):Health News:Text Messages from Santa | Santa goes GREEN by going MOBILE for The March of Dimes 2Health News:Ennis & Ennis, P.A. Announces Nationwide Free, Confidential, Consultations For Users Of Yaz And Yasmin Birth Control Pills 2Health News:Ennis & Ennis, P.A. Announces Nationwide Free, Confidential, Consultations For Users Of Yaz And Yasmin Birth Control Pills 3Health News:Sentinelle Medical Inc. Introduces Aegis(TM) Web Powered By Calgary Scientific's PureWeb Technology 2Health News:Sentinelle Medical Inc. Introduces Aegis(TM) Web Powered By Calgary Scientific's PureWeb Technology 3Health News:Black AIDS Institute Announces 2010 Board Election Results 2
... human welfare, spread of infectious disease and f...atellite imagery in order to acquire the proper ba...in, the geography professor of Kansas State Univer... Doug Goodin uses remote sensing, in combinati...
...ate University, Doug Goodin, makes use of satellit...and cover //changes on human health and food secur...with other types of data, to monitor and predict t... Decisions about Human Welfare," which was sponsor...
... have been able to zero in (on) the modalities of ... and other types of diseases. // Clinical trials o...drug to reduce the potency of a key enzyme, in cha...nn Collegiate Professor of Chemistry at U-M. 'Ou...
...ecialist, NHS can be freed from its’ problems, if ..., are reconsidered before they are implemented. //...vatization plan may make matters worse for the dep...ce has deteriorated. Though plans of privatization...
... the launch of BARACLUDE? (entecavir) for the tre...llowing its approval by the Drug Controller Genera...ed for the treatment of chronic hepatitis B virus ...histologically active disease. BARACLUDE? is...
... are repeatedly failing to implement rules that wi...atients //from contaminated surgical instruments. ...keeping instruments in sets so they can be traced ...to see that surgical instruments were not contamin...
Other Medicine News:Health News:Ecological Changes affects human health, food security 2Health News:Satellite Imagery to monitor the Social Impact Of Geographical Changes 2Health News:Autoimmune disorders studied in detail by U-M researchers. 2Health News:India Approves Baraclude? (entecavir) For ,Treatment Of Chronic HEPATITIS B 2
(Date:11/25/2009)...a-FirstCall/--ChinaSkyOne,Medical,Inc.("ChinaSkyOn...ullyintegratedpharmaceuticalcompanydevelopingandpr...ofChina("PRC"),today,announcedthattheCompanyrecent...fPharmaceuticalandBiologicalProducts("ICPBP")exami...umanProstateSpecific,Antigen(ColloidalGold)anditsD...
(Date:11/25/2009)...AccordingtoMillenniumResearchGroup(MRG),theglobala...early$3billionUSmarketfortraumafixationdeviceswill...etherecenteconomicslowdown.MRG,s USMarketsforTraum...highlydynamicoverthenextfiveyears,withcompetitorsi...dsegmentsofthetraumafixationmarket,fuelingmarketgr...
(Date:11/25/2009)...G,November25/PRNewswire/--,iThembaPharmaceuticals,...ttheyhavesignedacollaborativeagreementtojointlymar...sscomputationalchemistryandleaddiscoveryexpertise,...medicinaland,syntheticchemistrysupporttoprojectsid...ThembaPharmaceuticalsandPyxisDiscovery,alsoannounc...
Breaking Medicine Technology:China Sky One Medical, Inc. Achieved Progress in the Development of Two New Biological Testing Kits 2China Sky One Medical, Inc. Achieved Progress in the Development of Two New Biological Testing Kits 3US Trauma Fixation Device Market Not Seeing Signs of Slowdown 2US Trauma Fixation Device Market Not Seeing Signs of Slowdown 3iThemba Pharmaceuticals (Pty) Ltd and Pyxis Discovery B.V. Announce Collaborative Agreement to Offer a Combined Service Offering 2AUDIO from Medialink and Guardian 3A Breast Cancer Awareness Month Highlights Need for Critical Illness Insurance 59684 1International SOS Awarded TRICARE Overseas Program Contract 59681 1International SOS Awarded TRICARE Overseas Program Contract 59681 2FDA Approves Elitek 28R 29 28rasburicase 29 for Management of Plasma Uric Acid Levels in Adults with Leukemia Lymphoma and Solid Tumors Receiving A 5545 1FDA Approves Elitek 28R 29 28rasburicase 29 for Management of Plasma Uric Acid Levels in Adults with Leukemia Lymphoma and Solid Tumors Receiving A 5545 2FDA Approves Elitek 28R 29 28rasburicase 29 for Management of Plasma Uric Acid Levels in Adults with Leukemia Lymphoma and Solid Tumors Receiving A 5545 3FDA Approves Elitek 28R 29 28rasburicase 29 for Management of Plasma Uric Acid Levels in Adults with Leukemia Lymphoma and Solid Tumors Receiving A 5545 4FDA Approves Elitek 28R 29 28rasburicase 29 for Management of Plasma Uric Acid Levels in Adults with Leukemia Lymphoma and Solid Tumors Receiving A 5545 5FDA Approves Elitek 28R 29 28rasburicase 29 for Management of Plasma Uric Acid Levels in Adults with Leukemia Lymphoma and Solid Tumors Receiving A 5545 6FDA Approves Elitek 28R 29 28rasburicase 29 for Management of Plasma Uric Acid Levels in Adults with Leukemia Lymphoma and Solid Tumors Receiving A 5545 7
...IRE)--Jun 13, 2007 - EPIX,Pharmaceuticals, Inc. (N...ase 3 trial of PRX-00023, a novel long-acting 5-HT...at the 47th Annual New,Clinical Drug Evaluation Un...ting is sponsored by the National Institutes of,He...armacology., The presentation highlighted data fro...
..., WA -- (MARKET WIRE) -- June 14,2007 -- Targeted...rting data from the dose escalation arm of the ong...nts with inflammatory,arthritis. Philip J. Mease, ...ington School of Medicine, chief of rheumatology,c...acticing,physician with Seattle Rheumatology Assoc...
Other Medicine Technology:EPIX Pharmaceuticals Presents Findings from PRX-00023 Phase 3,Clinical Trial at 47th Annual NCDEU Meeting 2EPIX Pharmaceuticals Presents Findings from PRX-00023 Phase 3,Clinical Trial at 47th Annual NCDEU Meeting 3EPIX Pharmaceuticals Presents Findings from PRX-00023 Phase 3,Clinical Trial at 47th Annual NCDEU Meeting 4Targeted Genetics Reports Inflammatory Arthritis Clinical Data at,European Rheumatology Conference 2Targeted Genetics Reports Inflammatory Arthritis Clinical Data at,European Rheumatology Conference 3Targeted Genetics Reports Inflammatory Arthritis Clinical Data at,European Rheumatology Conference 4Targeted Genetics Reports Inflammatory Arthritis Clinical Data at,European Rheumatology Conference 5Targeted Genetics Reports Inflammatory Arthritis Clinical Data at,European Rheumatology Conference 6
Anti-MPO - ELISA (P-ANCA)
Myeloperoxidase (MPO) Enzyme-Linked Immunosorbent Assay (ELISA)
Iso-Insulin ELISA
RIDASCREEN Anti-RSV IgM Assay
Medicine Products: